Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Samuelsson

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Lancet (London, England)|November 9, 2004
Atenolol in hypertension: is it a wise choice?Bo Carlberg, Ola Samuelsson, Lars Hjalmar Lindholm
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 12, 2011
The effect of decreasing renal function on lipoprotein profilesPer-Ola Attman, Ola Samuelsson, Petar Alaupovic
Lancet (London, England)|November 1, 2005
Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysisLars Hjalmar Lindholm, Bo Carlberg, Ola Samuelsson
Lakartidningen|February 17, 2005
[Does Kent Forsen possibly have a complete picture about atenolol?]Bo Carlberg, Ola Samuelsson, Lars H Lindholm
Journal of Hypertension|October 21, 2006
Beta blockers in primary hypertension: Do age and type of beta-blocker matter?Lars Hjalmar Lindholm, Bo Carlberg, Ola Samuelsson
Lakartidningen|October 30, 2013
[Hyperbaric oxygen therapy is effective for diabetic foot ulcers. Recent randomized controlled trials have provided better knowledge]Anders Rosén, Nicklas Oscarsson, Per Arnell, et al.
Lakartidningen|June 26, 2008
[Determination of cystatin C. Not a reliable way to estimate renal function--and rather expensive!]Aso Saeed, Maria K Svensson, Hans Herlitz, et al.
British Journal of Clinical Pharmacology|February 26, 2008
Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversionBengt Hamrén, Hans Ericsson, Ola Samuelsson, et al.
Clinical Drug Investigation|May 31, 2007
Candesartan cilexetil in haemodialysis patientsPia Ottosson, Per-Ola Attman, Ann-Charlotte Agren, et al.
Hypertension (Dallas, Tex. : 1979)|July 14, 2004
Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertensionThórdís Hrafnkelsdóttir, Pia Ottosson, Thorarinn Gudnason, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Lancet (London, England)|November 9, 2004
Atenolol in hypertension: is it a wise choice?Bo Carlberg, Ola Samuelsson, Lars Hjalmar Lindholm
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 12, 2011
The effect of decreasing renal function on lipoprotein profilesPer-Ola Attman, Ola Samuelsson, Petar Alaupovic
Lancet (London, England)|November 1, 2005
Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysisLars Hjalmar Lindholm, Bo Carlberg, Ola Samuelsson
Lakartidningen|February 17, 2005
[Does Kent Forsen possibly have a complete picture about atenolol?]Bo Carlberg, Ola Samuelsson, Lars H Lindholm
Journal of Hypertension|October 21, 2006
Beta blockers in primary hypertension: Do age and type of beta-blocker matter?Lars Hjalmar Lindholm, Bo Carlberg, Ola Samuelsson
Lakartidningen|October 30, 2013
[Hyperbaric oxygen therapy is effective for diabetic foot ulcers. Recent randomized controlled trials have provided better knowledge]Anders Rosén, Nicklas Oscarsson, Per Arnell, et al.
Lakartidningen|June 26, 2008
[Determination of cystatin C. Not a reliable way to estimate renal function--and rather expensive!]Aso Saeed, Maria K Svensson, Hans Herlitz, et al.
British Journal of Clinical Pharmacology|February 26, 2008
Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversionBengt Hamrén, Hans Ericsson, Ola Samuelsson, et al.
Clinical Drug Investigation|May 31, 2007
Candesartan cilexetil in haemodialysis patientsPia Ottosson, Per-Ola Attman, Ann-Charlotte Agren, et al.
Hypertension (Dallas, Tex. : 1979)|July 14, 2004
Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertensionThórdís Hrafnkelsdóttir, Pia Ottosson, Thorarinn Gudnason, et al.
Pageof 5